CA3253332A1 - STABILIZED PRE-FUSION HMPV FUSION PROTEINS - Google Patents
STABILIZED PRE-FUSION HMPV FUSION PROTEINSInfo
- Publication number
- CA3253332A1 CA3253332A1 CA3253332A CA3253332A CA3253332A1 CA 3253332 A1 CA3253332 A1 CA 3253332A1 CA 3253332 A CA3253332 A CA 3253332A CA 3253332 A CA3253332 A CA 3253332A CA 3253332 A1 CA3253332 A1 CA 3253332A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- hmpv
- protein
- seq
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22173131 | 2022-05-12 | ||
| EP22173131.8 | 2022-05-12 | ||
| PCT/EP2023/062652 WO2023217988A1 (en) | 2022-05-12 | 2023-05-11 | Stabilized pre-fusion hmpv fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3253332A1 true CA3253332A1 (en) | 2023-11-16 |
Family
ID=81653543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3253332A Pending CA3253332A1 (en) | 2022-05-12 | 2023-05-11 | STABILIZED PRE-FUSION HMPV FUSION PROTEINS |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4522209A1 (enExample) |
| JP (1) | JP2025521082A (enExample) |
| KR (1) | KR20250010642A (enExample) |
| CN (1) | CN119562826A (enExample) |
| AU (1) | AU2023269241A1 (enExample) |
| CA (1) | CA3253332A1 (enExample) |
| CL (1) | CL2024003418A1 (enExample) |
| CO (1) | CO2024015386A2 (enExample) |
| CR (1) | CR20240493A (enExample) |
| DO (1) | DOP2024000230A (enExample) |
| GE (1) | GEAP202516650A (enExample) |
| IL (1) | IL316911A (enExample) |
| JO (1) | JOP20240256A1 (enExample) |
| MX (1) | MX2024013959A (enExample) |
| PE (1) | PE20251395A1 (enExample) |
| WO (1) | WO2023217988A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026504862A (ja) | 2023-01-18 | 2026-02-10 | ファイザー・インク | 呼吸器疾患に対するワクチン |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025144636A1 (en) * | 2023-12-26 | 2025-07-03 | The Scripps Research Institute | ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES |
| WO2025163460A2 (en) * | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| JP7382230B2 (ja) | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組み換えウイルスレプリコン系及びその使用 |
| BR112019011661A2 (pt) | 2016-12-05 | 2020-01-07 | Synthetic Genomics, Inc. | Composições e métodos para aumentar expressão de gene |
| US12559544B2 (en) * | 2019-05-21 | 2026-02-24 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| CN116615235A (zh) * | 2020-10-09 | 2023-08-18 | 得克萨斯州大学系统董事会 | 融合前稳定的hmpv f蛋白 |
-
2023
- 2023-05-11 GE GEAP202516650A patent/GEAP202516650A/en unknown
- 2023-05-11 CN CN202380053513.6A patent/CN119562826A/zh active Pending
- 2023-05-11 KR KR1020247040979A patent/KR20250010642A/ko active Pending
- 2023-05-11 JP JP2024566227A patent/JP2025521082A/ja active Pending
- 2023-05-11 IL IL316911A patent/IL316911A/en unknown
- 2023-05-11 CA CA3253332A patent/CA3253332A1/en active Pending
- 2023-05-11 CR CR20240493A patent/CR20240493A/es unknown
- 2023-05-11 WO PCT/EP2023/062652 patent/WO2023217988A1/en not_active Ceased
- 2023-05-11 PE PE2024002522A patent/PE20251395A1/es unknown
- 2023-05-11 AU AU2023269241A patent/AU2023269241A1/en active Pending
- 2023-05-11 EP EP23727473.3A patent/EP4522209A1/en active Pending
-
2024
- 2024-11-08 CL CL2024003418A patent/CL2024003418A1/es unknown
- 2024-11-11 MX MX2024013959A patent/MX2024013959A/es unknown
- 2024-11-11 JO JOJO/P/2024/0256A patent/JOP20240256A1/ar unknown
- 2024-11-11 DO DO2024000230A patent/DOP2024000230A/es unknown
- 2024-11-12 CO CONC2024/0015386A patent/CO2024015386A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024003418A1 (es) | 2025-08-01 |
| JOP20240256A1 (ar) | 2024-11-11 |
| AU2023269241A1 (en) | 2024-11-21 |
| WO2023217988A1 (en) | 2023-11-16 |
| IL316911A (en) | 2025-01-01 |
| MX2024013959A (es) | 2025-02-10 |
| CO2024015386A2 (es) | 2024-11-28 |
| DOP2024000230A (es) | 2025-02-16 |
| GEAP202516650A (en) | 2025-03-10 |
| CN119562826A (zh) | 2025-03-04 |
| JP2025521082A (ja) | 2025-07-08 |
| KR20250010642A (ko) | 2025-01-21 |
| CR20240493A (es) | 2025-01-29 |
| PE20251395A1 (es) | 2025-05-22 |
| EP4522209A1 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4522209A1 (en) | Stabilized pre-fusion hmpv fusion proteins | |
| JP7362819B2 (ja) | 安定化された可溶性融合前ｒｓｖ ｆタンパク質 | |
| US10967057B2 (en) | Zika viral antigen constructs | |
| US20230242593A1 (en) | Zika viral antigen constructs | |
| US20210347828A1 (en) | RNA Replicon Encoding a Stabilized Corona Virus Spike Protein | |
| CA2814386C (en) | Antigen delivery platforms | |
| EP4448802A1 (en) | Stabilized pre-fusion hmpv fusion proteins | |
| US20210346492A1 (en) | SARS-CoV-2 Vaccines | |
| WO2021209970A1 (en) | Sars cov-2 spike protein construct | |
| KR20230165275A (ko) | 안정화된 융합 전 piv3 f 단백질 | |
| WO2022157153A2 (en) | Therapeutic viral vaccine | |
| WO2023047349A1 (en) | Stabilized coronavirus spike protein fusion proteins | |
| EP4294436A1 (en) | Stabilized pre-fusion rsv fb fantigens | |
| WO2023047348A1 (en) | Stabilized corona virus spike protein fusion proteins | |
| HK40073646A (en) | Zika viral antigen constructs | |
| EP4590690A1 (en) | Pre-fusion human piv1 f proteins | |
| CN116745408A (zh) | 稳定的冠状病毒刺突蛋白融合蛋白 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241112 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250205 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250205 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250409 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250410 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251001 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260409 |